UROONCO PCa associate editor Dr. Constance Thibault (FR) talks to Prof. Christophe Hennequin from Saint-Louis Hospital, France about the GETUG-AFU 18 trial results he presented at ASCO GU24 in San Francisco.

Prof. Hennequin shares details on the design of the study, followed by the trial results of long-term dose escalation (80 vs 70Gy) combined with long-term androgen deprivation in high-risk prostate cancer. 

For more details on this study, you can read this abstract on the UROONCO Prostate Cancer educational platform.